Utility of Ischemia Modified Albumin as an Early Marker for Diagnosis of Acute Coronary Syndrome

  • Bijaya Mishra Department of Biochemistry ,BPKIHS, Dharan, Sunsari, Nepal.
  • Sunil Pandey Department of Biochemistry ,BPKIHS, Dharan, Sunsari, Nepal.
  • Surya Raj Niraula Department of School of Public Health and Community Medicine, BPKIHS, Dharan, Sunsari, Nepal.
  • Bijendra Kumar Rai Department of General Practice and Emergency Medicine, BPKIHS, Dharan, Sunsari, Nepal.
  • Prahlad Karki Department of Internal Medicine, BPKIHS, Dharan, Sunsari, Nepal.
  • Nirmal Baral Department of Biochemistry ,BPKIHS, Dharan, Sunsari, Nepal.
  • Madhab Lamsal Department of Biochemistry, BPKIHS, Dharan, Sunsari, Nepal.

Abstract

Background: The diagnosis of acute coronary syndrome remains challenging, as cardiac troponins and creatine kinase-MB do not detect myocardial ischemia. Ischemia modified albumin is biomarker positive within 6-10 minutes following ischemic onset, where oxygen free radicals leads to reduction in binding capacity of human serum albumin to transitional metal-cobalt. The objective of this study was to compare ischemia modified albumin between acute coronary syndrome patients and healthy controls, and evaluate diagnostic performance of ischemia modified albumin compared to cardiac troponins, creatine kinase-MB and electrocardiogram in acute coronary syndrome patients.
Methods: Fifty ACS patients and 50 healthy controls were enrolled in this cross-sectional study. Ischemia modified albumin was measured after addition of known amount of cobalt to human serum albumin, followed by spectrophotometric determination of unbound cobalt fraction at 470 nm using dithiothreitol as coloring agent. Independent student t-test and One-way ANOVA to compare differences of mean between groups; diagnostic sensitivity and specificity of ischemia modified albumin was determined by receiver operating characteristic curve; McNemar-test was used to assess diagnostic performance of entire test parameters, when used alone and in combinations.
Results: Ischemia modified albumin was significantly higher in acute coronary syndrome patients compared to controls (0.823±0.191 vs 0.410±0.081)(p<0.001). Receiver operating characteristic curve derived optimal cut-off of 0.475 Absorbance unit had sensitivity and specificity of 92% and 82% respectively (area under curve- 0.96). However, no significant differences in mean ischemia modified albumin values between three categories of acute coronary syndrome were seen. Sensitivity of ischemia modified albumin assay (92%) was significantly higher compared to electrocardiogram (72%), cardiac troponin I (18%), and creatine kinase-MB(42%).
Conclusions: Ischemia modified albumin is elevated in acute coronary syndrome patients with better diagnostic performance compared to electrocardiogram, cardiac troponin I, and creatine kinase-MB for early diagnosis, however, with limited ability to discriminate between ST-elevation myocardial infarction, non-ST-elevation myocardial infarction and unstable angina.

Published
2018-03-13
How to Cite
MISHRA, Bijaya et al. Utility of Ischemia Modified Albumin as an Early Marker for Diagnosis of Acute Coronary Syndrome. Journal of Nepal Health Research Council, [S.l.], v. 16, n. 1, p. 16-21, mar. 2018. ISSN 1999-6217. Available at: <http://jnhrc.com.np/index.php/jnhrc/article/view/1002>. Date accessed: 23 oct. 2018.